{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T22:11:16Z","timestamp":1780697476427,"version":"3.54.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T00:00:00Z","timestamp":1620777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T00:00:00Z","timestamp":1620777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"BioMarin"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Utility studies enable preference-based quantification of a disease\u2019s impact on patients\u2019 health-related quality of life (HRQoL). It is often difficult to obtain utility values for rare, neurodegenerative conditions due to cognitive burden of direct elicitation methods, and the limited size of patient\/caregiver populations. CLN2 disease (neuronal ceroid lipofuscinosis type 2) is an ultra-rare, progressive condition, for which there are no published utility data fully capturing all disease stages. This case study demonstrates how utility values can be estimated for ultra-rare paediatric diseases by asking clinicians to complete EQ-5D-5L questionnaires based on vignettes describing the stages of CLN2 disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An indirect elicitation method using proxy-reporting by clinical experts was adopted. Eighteen vignettes were developed, describing nine progressive disease stages as defined by motor and language domain scores of the CLN2 Clinical Rating Scale, in individuals treated with cerliponase alfa or standard care. Eight clinical experts with experience of treating CLN2 disease with cerliponase alfa and current standard care completed the proxy version 2 EQ-5D-5L online after reading these vignettes. Resulting scores were converted to EQ-5D-5L utility values for each disease stage, using UK, German and Spanish value sets.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Utility values, which are typically anchored by 0 (equivalent to death) and 1 (full health), decreased with CLN2 disease progression (results spanned the maximum range of the utility scale). Assigned utility values were consistently higher for patients receiving cerliponase alfa than standard care; differences were statistically significant for the 6 most severe disease stages (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Analysis of the individual dimensions of the EQ-5D-5L showed that greatest differences between patients treated with cerliponase alfa and standard care occurred in the pain dimension (differences in mean scores ranged between no difference and 1.8), with notable differences also observed in the anxiety\/depression dimension (differences in mean scores ranged between 0.1 and 1.0).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study demonstrates a feasible methodology for eliciting utility values in CLN2 disease, indicating HRQoL declines with disease progression. Vignettes describing patients receiving cerliponase alfa were consistently assigned higher utility values for the same disease state, suggesting this treatment improves HRQoL compared with standard care.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> NCT01907087, NCT02485899.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-01829-x","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T18:03:00Z","timestamp":1620842580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Investigating health-related quality of life in rare diseases: a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type 2)"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9712-6122","authenticated-orcid":false,"given":"Paul","family":"Gissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Specchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Olaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wrik","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ruban-Fell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Camp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zlatko","family":"Sisic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schwering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Wibbeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Trivisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Nickel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,12]]},"reference":[{"issue":"11","key":"1829_CR1","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/hec.1006","volume":"14","author":"S Petrou","year":"2005","unstructured":"Petrou S, Hockley C. An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population. Health Econ. 2005;14(11):1169\u201389.","journal-title":"Health Econ"},{"key":"1829_CR2","volume-title":"What are health utilities?","author":"K Tolley","year":"2014","unstructured":"Tolley K. What are health utilities? London: Hayward Medical Communications; 2014."},{"key":"1829_CR3","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015."},{"key":"1829_CR4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1477-7525-1-80","volume":"1","author":"L Prieto","year":"2003","unstructured":"Prieto L, Sacrist\u00e1n JA. Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual Life Outcomes. 2003;1:80.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"1829_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/14737167.2016.1179116","volume":"16","author":"SM Montgomery","year":"2016","unstructured":"Montgomery SM, Kusel J. The prevalence of child-specific utilities in NICE appraisals for paediatric indications: rise of the economic orphans? Expert Rev Pharmacoecon Outcomes Res. 2016;16(3):347\u201350.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"1829_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jpeds.2009.03.007","volume":"155","author":"LA Prosser","year":"2009","unstructured":"Prosser LA. Current challenges and future research in measuring preferences for pediatric health outcomes. J Pediatr. 2009;155(1):7\u20139.","journal-title":"J Pediatr"},{"key":"1829_CR7","volume-title":"NICE DSU technical support document 11: alternatives to EQ-5D for generating health state utility values","author":"J Brazier","year":"2011","unstructured":"Brazier J, Rowen D. NICE DSU technical support document 11: alternatives to EQ-5D for generating health state utility values. London: National Institute for Health and Care Excellence (NICE); 2011."},{"key":"1829_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.pediatrneurol.2017.01.034","volume":"69","author":"RE Williams","year":"2017","unstructured":"Williams RE, Adams HR, Blohm M, Cohen-Pfeffer JL, de Los RE, Denecke J, et al. Management strategies for CLN2 disease. Pediatr Neurol. 2017;69:102\u201312.","journal-title":"Pediatr Neurol"},{"issue":"3","key":"1829_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1399-0004.2008.01054.x","volume":"74","author":"S Moore","year":"2008","unstructured":"Moore S, Buckley D, MacMillan A, Marshall H, Steele L, Ray P, et al. The clinical and genetic epidemiology of neuronal ceroid lipofuscinosis in Newfoundland. Clin Genetics. 2008;74(3):213\u201322.","journal-title":"Clin Genetics"},{"key":"1829_CR10","unstructured":"National Institute for Health and Clinical Excellence (NICE). Final scope for the evaluation of cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2. 2019."},{"key":"1829_CR11","doi-asserted-by":"crossref","unstructured":"Chang M, Cooper JD, Davidson BL, van Diggelen OP, Elleder M, Goebel HH, et al. CLN2. In: The neuronal ceroid lipofuscinoses [Internet]. Oxford University Press; 2011, p. 80\u2013109.","DOI":"10.1093\/med\/9780199590018.003.0007"},{"issue":"1","key":"1829_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnen\/62.1.1","volume":"62","author":"M Haltia","year":"2003","unstructured":"Haltia M. The neuronal ceroid-lipofuscinoses. J Neuropathol Exp Neurol. 2003;62(1):1\u201313.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"1829_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/ajmg.10660","volume":"112","author":"R Steinfeld","year":"2002","unstructured":"Steinfeld R, Heim P, von Gregory H, Meyer K, Ullrich K, Goebel HH, et al. Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations. Am J Med Genetics. 2002;112(4):347\u201354.","journal-title":"Am J Med Genetics"},{"key":"1829_CR14","doi-asserted-by":"publisher","first-page":"FV04-03","DOI":"10.1055\/s-0036-1583730","volume":"47","author":"M Nickel","year":"2016","unstructured":"Nickel M, Jacoby D, Lezius S, Down M, Simonati A, Genter F, et al. Natural history of CLN2 disease: quantitative assessment of disease characteristics and rate of progression in an international cohort of 137 patients. Neuropediatrics. 2016;47:FV04-03.","journal-title":"Neuropediatrics"},{"key":"1829_CR15","unstructured":"Mole S, Williams R. Neuronal ceroid-lipofuscinoses. 2001 [Updated 2013]. In: Gene reviews [Internet]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1428\/."},{"key":"1829_CR16","unstructured":"European Medicines Agency. Brineura, cerliponase alfa\u2014summary of product characteristics. 2017."},{"key":"1829_CR17","unstructured":"ClinicalTrials.gov. A multicenter, multinational, extension study to evaluate the long-term efficacy and safety of BMN 190 in patients with CLN2 disease. 2015. Updated November 2017. https:\/\/ClinicalTrials.gov\/. (Identification No. NCT02485899)."},{"key":"1829_CR18","doi-asserted-by":"crossref","unstructured":"Wyrwich KW, Schulz A, Nickel M, Slasor P, Ajayi T, Jacoby DR, et al. An adapted clinical measurement tool for the key symptoms of CLN2 disease. J Inborn Errors Metab Screen 2018;6.","DOI":"10.1177\/2326409818788382"},{"issue":"20","key":"1829_CR19","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","volume":"378","author":"A Schulz","year":"2018","unstructured":"Schulz A, Ajayi T, Specchio N, de Los RE, Gissen P, Ballon D, et al. Study of intraventricular cerliponase alfa for CLN2 disease. N Engl J Med. 2018;378(20):1898\u2013907.","journal-title":"N Engl J Med"},{"key":"1829_CR20","unstructured":"EuroQol. EQ-5D-5L-About. https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-5l-about\/."},{"issue":"1","key":"1829_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hec.3564","volume":"27","author":"NJ Devlin","year":"2017","unstructured":"Devlin NJ, Shah KK, Feng Y, Mulhern B, Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2017;27(1):7\u201322.","journal-title":"Health Econ"},{"key":"1829_CR22","unstructured":"National Institute for Health and Clinical Excellence (NICE). Position statement on use of the EQ-5D-5L valuation set. 2017. https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/NICE-guidance\/NICE-technology-appraisal-guidance\/eq5d5l_nice_position_statement.pdf."},{"issue":"5","key":"1829_CR23","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, Janssen MF, Feng Y-S, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708\u201315.","journal-title":"Value Health"},{"issue":"6","key":"1829_CR24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40273-018-0615-8","volume":"36","author":"K Ludwig","year":"2018","unstructured":"Ludwig K, Graf von der Schulenburg JM, Greiner W. German value set for the EQ-5D-5L. Pharmacoeconomics. 2018;36(6):663\u201374.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"1829_CR25","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jval.2017.10.023","volume":"21","author":"JM Ramos-Go\u00f1i","year":"2018","unstructured":"Ramos-Go\u00f1i JM, Craig BM, Oppe M, Ramallo-Fari\u00f1a Y, Pinto-Prades JL, Luo N, et al. Handling data quality issues to estimate the Spanish EQ-5D-5L value set using a hybrid interval regression approach. Value Health. 2018;21(5):596\u2013604.","journal-title":"Value Health"},{"issue":"1","key":"1829_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12955-018-0908-9","volume":"16","author":"J O'Hara","year":"2018","unstructured":"O\u2019Hara J, Walsh S, Camp C, Mazza G, Carroll L, Hoxer C, et al. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health Qual Life Outcomes. 2018;16(1):84.","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"1829_CR27","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1037\/1040-3590.6.4.284","volume":"6","author":"DV Cicchetti","year":"1994","unstructured":"Cicchetti DV. Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychol Assess. 1994;6(4):284.","journal-title":"Psychol Assess"},{"issue":"9","key":"1829_CR28","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1192\/pb.bp.110.033241","volume":"35","author":"R Cairns","year":"2011","unstructured":"Cairns R, Brown P, Grant-Peterkin H, Khondoker MR, Owen GS, Richardson G, et al. Judgements about deprivation of liberty made by various professionals: comparison study. Psychiatrist. 2011;35(9):344\u20139.","journal-title":"Psychiatrist"},{"issue":"4","key":"1829_CR29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1017\/S0714980809990195","volume":"28","author":"J Ploeg","year":"2009","unstructured":"Ploeg J, Denton M, Tindale J, Hutchison B, Brazil K, Akhtar-Danesh N, et al. Older adults\u2019 awareness of community health and support services for dementia care. Can J Aging. 2009;28(4):359\u201370.","journal-title":"Can J Aging"},{"issue":"5","key":"1829_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1017\/S0266462320000665","volume":"36","author":"M Meregaglia","year":"2020","unstructured":"Meregaglia M, Nicod E, Drummond M. The estimation of health state utility values in rare diseases: overview of existing techniques. Int J Technol Assess Health Care. 2020;36(5):469\u201373.","journal-title":"Int J Technol Assess Health Care"},{"key":"1829_CR31","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2147\/CEOR.S214084","volume":"11","author":"AJ Lloyd","year":"2019","unstructured":"Lloyd AJ, Thompson R, Gallop K, Teynor M. Estimation of the quality of life benefits associated with treatment for spinal muscular atrophy. Clinicoecon Outcomes Res. 2019;11:615\u201322.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"1829_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1477-7525-10-35","volume":"10","author":"RH Osborne","year":"2012","unstructured":"Osborne RH, Dalton A, Hertel J, Schrover R, Smith DK. Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study. Health Qual Life Outcomes. 2012;10(1):35.","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"1829_CR33","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s11136-018-1831-6","volume":"27","author":"JL Wolstenholme","year":"2018","unstructured":"Wolstenholme JL, Bargo D, Wang K, Harnden A, R\u00e4is\u00e4nen U, Abel L. Preference-based measures to obtain health state utility values for use in economic evaluations with child-based populations: a review and UK-based focus group assessment of patient and parent choices. Qual Life Res. 2018;27(7):1769\u201380.","journal-title":"Qual Life Res"},{"key":"1829_CR34","doi-asserted-by":"publisher","first-page":"b2688","DOI":"10.1136\/bmj.b2688","volume":"339","author":"D Arnold","year":"2009","unstructured":"Arnold D, Girling A, Stevens A, Lilford R. Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis. BMJ. 2009;339:b2688.","journal-title":"BMJ"},{"issue":"8","key":"1829_CR35","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2165\/11591570-000000000-00000","volume":"29","author":"WJ Ungar","year":"2011","unstructured":"Ungar WJ. Challenges in health state valuation in paediatric economic evaluation: are QALYs contraindicated? Pharmacoeconomics. 2011;29(8):641\u201352.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1829_CR36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1046\/j.1524-4733.1999.02210.x","volume":"2","author":"NK Leidy","year":"1999","unstructured":"Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health J Int Soc Pharmacoecon Outcomes Res. 1999;2(2):113\u201327.","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"issue":"1","key":"1829_CR37","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1524-4733.2004.71273.x","volume":"7","author":"LS Matza","year":"2004","unstructured":"Matza LS, Swensen AR, Flood EM, Secnik K, Leidy NK. Assessment of health-related quality of life in children: a review of conceptual, methodological, and regulatory issues. Value Health J Int Soc Pharmacoecon Outcomes Res. 2004;7(1):79\u201392.","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"issue":"4","key":"1829_CR38","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1023\/A:1012253723272","volume":"10","author":"C Eiser","year":"2001","unstructured":"Eiser C, Morse R. Can parents rate their child\u2019s health-related quality of life? Results of a systematic review. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2001;10(4):347\u201357.","journal-title":"Qual Life Res Int J Qual Life Asp Treat Care Rehabil"},{"issue":"7","key":"1829_CR39","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s11136-014-0642-7","volume":"23","author":"Y Lim","year":"2014","unstructured":"Lim Y, Velozo C, Bendixen RM. The level of agreement between child self-reports and parent proxy-reports of health-related quality of life in boys with Duchenne muscular dystrophy. Qual Life Res. 2014;23(7):1945\u201352.","journal-title":"Qual Life Res"},{"issue":"1","key":"1829_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12955-016-0476-9","volume":"14","author":"TG Capitello","year":"2016","unstructured":"Capitello TG, Fiorilli C, Placidi S, Vallone R, Drago F, Gentile S. What factors influence parents\u2019 perception of the quality of life of children and adolescents with neurocardiogenic syncope? Health Qual Life Outcomes. 2016;14(1):79.","journal-title":"Health Qual Life Outcomes"},{"issue":"10","key":"1829_CR41","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/jpepsy\/jsn036","volume":"33","author":"CB McClellan","year":"2008","unstructured":"McClellan CB, Schatz J, Sanchez C, Roberts CW. Validity of the pediatric quality of life inventory for youth with sickle cell disease. J Pediatric Psychol. 2008;33(10):1153\u201362.","journal-title":"J Pediatric Psychol"},{"key":"1829_CR42","volume-title":"UK population norms for EQ-5D","author":"P Kind","year":"1999","unstructured":"Kind P, Hardman G, Macran S. UK population norms for EQ-5D. Centre for Health Economics: University of York; 1999."},{"issue":"1","key":"1829_CR43","doi-asserted-by":"publisher","first-page":"1618661","DOI":"10.1080\/20016689.2019.1618661","volume":"7","author":"N Germain","year":"2019","unstructured":"Germain N, Aball\u00e9a S, Toumi M. Measuring the health-related quality of life in young children: how far have we come? J Mark Access Health Policy. 2019;7(1):1618661.","journal-title":"J Mark Access Health Policy"},{"issue":"1","key":"1829_CR44","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1212\/WNL.53.1.162","volume":"53","author":"NK Leidy","year":"1999","unstructured":"Leidy NK, Elixhauser A, Vickrey B, Means E, Willian M. Seizure frequency and the health-related quality of life of adults with epilepsy. Neurology. 1999;53(1):162.","journal-title":"Neurology"},{"key":"1829_CR45","unstructured":"EuroQoL. EQ-5D\u2014value sets. https:\/\/euroqol.org\/publications\/key-euroqol-references\/value-sets\/."},{"issue":"2","key":"1829_CR46","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/WAD.0b013e318065c4a9","volume":"21","author":"F Bostrom","year":"2007","unstructured":"Bostrom F, Jonsson L, Minthon L, Londos E. Patients with dementia with lewy bodies have more impaired quality of life than patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21(2):150\u20134.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"1","key":"1829_CR47","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jval.2016.09.2398","volume":"20","author":"G Ward Fuller","year":"2017","unstructured":"Ward Fuller G, Hernandez M, Pallot D, Lecky F, Stevenson M, Gabbe B. Health state preference weights for the glasgow outcome scale following traumatic brain injury: a systematic review and mapping study. Value Health. 2017;20(1):141\u201351.","journal-title":"Value Health"},{"issue":"3","key":"1829_CR48","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.pbj.2017.02.002","volume":"2","author":"J Peres","year":"2017","unstructured":"Peres J, Martins R, Alves JD, Valverde A. Rituximab in generalized myasthenia gravis: clinical, quality of life and cost\u2013utility analysis. Porto Biomed J. 2017;2(3):81\u20135.","journal-title":"Porto Biomed J"},{"issue":"1","key":"1829_CR49","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1524-4733.2006.00144.x","volume":"10","author":"M Orme","year":"2007","unstructured":"Orme M, Kerrigan J, Tyas D, Russell N, Nixon R. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health. 2007;10(1):54\u201360.","journal-title":"Value Health"},{"issue":"20","key":"1829_CR50","first-page":"1","volume":"10","author":"SW Goodacre","year":"2012","unstructured":"Goodacre SW, Wilson RW, Bradburn M, Santarelli M, Nicholl JP. Health utility after emergency medical admission: a cross-sectional survey. Health Qual Life Outcomes. 2012;10(20):1\u20139.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"1829_CR51","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ijchp.2014.12.001","volume":"15","author":"SC Evans","year":"2015","unstructured":"Evans SC, Roberts MC, Keeley JW, Blossom JB, Amaro CM, Garcia AM, et al. Vignette methodologies for studying clinicians\u2019 decision-making: validity, utility, and application in ICD-11 field studies. Int J Clin Health Psychol IJCHP. 2015;15(2):160\u201370.","journal-title":"Int J Clin Health Psychol IJCHP"},{"issue":"4","key":"1829_CR52","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3111\/13696998.2012.670175","volume":"15","author":"P Swinburn","year":"2012","unstructured":"Swinburn P, Wang J, Chandiwana D, Mansoor W, Lloyd A. Elicitation of health state utilities in neuroendocrine tumours. J Med Econ. 2012;15(4):681\u20137.","journal-title":"J Med Econ"},{"issue":"5","key":"1829_CR53","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jval.2018.02.008","volume":"21","author":"I Pearson","year":"2018","unstructured":"Pearson I, Rothwell B, Olaye A, Knight C. Economic modeling considerations for rare diseases. Value Health. 2018;21(5):515\u201324.","journal-title":"Value Health"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01829-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01829-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01829-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T18:06:18Z","timestamp":1620842778000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01829-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,12]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1829"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01829-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,12]]},"assertion":[{"value":"9 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No patient data was collected during this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the results presented in this article are in aggregate form, and no personally identifiable information was used for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PG, NS, CS, EW, MT, LL, MN, AS: no competing interests to declare; MJ, CC, TB: employees and shareholders of BioMarin; ZS, AO: employee and shareholder of BioMarin at time of study initiation; WG: employee of Costello Medical at time of study initiation; BRF, AG: employees of Costello Medical; AM: the BDFA receives funding from BioMarin but did not receive any funding associated with this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"217"}}